ALDX

Aldeyra Therapeutics Inc. Common Stock (ALDX)

Stock · NASDAQ · Health Care

$0.7as of 10/16/2026

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

September 28, 2026

Biotech Sector News Dominates; No Specific ALDX Updates. Recent news coverage focuses on clinical trial results for other biotechnology companies, such as ACAD and Vertex, rather than Aldeyra Therapeutics. There are no new company-specific announcements or trial updates for ALDX in the provided reports. The stock is currently trading near its 52-week low, reflecting broader sector sentiment rather than isolated corporate news.

Price chart

Open in TradingView

Active signals

200 SMA Touch0.0%
Resistance level
$1.5
Industry
Biotechnology: Pharmaceutical Preparations

ALDX Signal Track Record

How signals performed across all stocks →

What ALDX's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.

SignalTimesMedian 20-session returnHigher after 20 sessions
Volume Spike35+6.4%66%
Bollinger Band Breakout26+8.0%62%
Bollinger Band Breakdown19+3.1%58%
200-Day Moving Average TouchActive now10-6.3%30%
Any 20-session window (baseline)+0.9%53%

Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.

About ALDX

Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lympho…

Sector
Health Care
Industry
Biotechnology: Pharmaceutical Preparations
Employees
6

Fundamentals

1-day range
$0.882$0.94
Market cap
$95.91M
P/E (trailing)
—
P/E (forward)
-3.29
EPS (trailing)
$-0.38
Dividend yield
—
Beta
1.19
Avg. volume
1.17M
52-week range
$0.8619$5.93
Next earnings: November 4, 2026 · EPS estimate $-0.08confirmed

Forecasts

5 analyst ratings

Buy 83%
Hold 17%
Sell 0%
1-year price forecast
High
$13
+1757.1%
Median
$5
+614.3%
Low
$2
+185.7%

Aldeyra Therapeutics Inc. Common Stock Competitors

Chosen by industry and closest market cap.

  • ALDX
    Aldeyra Therapeutics Inc. Common Stock
    $0.7
    ▼ 5.02%
    Market cap $95.91MP/E —
    $0.8619$5.93
  • ONCY
    Oncolytics Biotech Inc. Common Stock
    $0.5
    ▼ 9.09%
    Market cap $95.55MP/E —
    $1.48$4.49
  • RANI
    Rani Therapeutics Holdings Inc. Class A Common Stock
    $0.641
    ▼ 5.74%
    Market cap $96.76MP/E —
    $0.462$3.87
  • HRTX
    Heron Therapeutics Inc. Common Stock
    $0.36
    ▼ 5.26%
    Market cap $94.45MP/E —
    $0.261$1.58
  • ZYBT
    Zhengye Biotechnology Holding Limited Class A Ordinary Shares
    $1.4
    ▼ 6.67%
    Market cap $99.05MP/E —
    $0.6155$8.01
  • VRCA
    Verrica Pharmaceuticals Inc. Common Stock
    $3.6
    ▼ 4.89%
    Market cap $92.08MP/E —
    $3.28$9.82
  • FBIO
    Fortress Biotech Inc. Common Stock
    $1.87
    ▼ 2.09%
    Market cap $92.02MP/E 0.58
    $1.88$4.53

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

Insider Activity

Insider Actions →
Acquired
545.2K
Disposed
0

Institutional Ownership

March 31, 2026

Total shares held
36.91M
Total value held
$60.00M
Institutional holders
119
Top holders this quarter
  • Unknown5.48M
  • Unknown3.76M
  • Unknown2.83M
  • Unknown2.36M
  • Unknown2.15M
  • Unknown1.50M
  • Unknown1.40M
  • Unknown1.25M
  • Unknown1.25M
  • Unknown1.14M

See the full, filterable feed with live charts on the MarketWall dashboard.

We use analytics to understand how market-wall is used. No personal data is sold.